Other equities analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Monday, December 23rd. BidaskClub upgraded shares of Kamada from a “sell” rating to a “hold” rating in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.17.
KMDA opened at $6.51 on Friday. The firm has a market cap of $298.28 million, a P/E ratio of 7.66 and a beta of 1.36. The firm has a 50-day moving average of $6.67 and a 200 day moving average of $6.02. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.49 and a current ratio of 6.14. Kamada has a fifty-two week low of $4.91 and a fifty-two week high of $8.00.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $0.13 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.13. The company had revenue of $32.07 million during the quarter, compared to analyst estimates of $31.63 million. Kamada had a net margin of 24.16% and a return on equity of 28.62%. Equities research analysts predict that Kamada will post 0.55 earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of the business. Eagle Ridge Investment Management purchased a new stake in shares of Kamada in the third quarter worth about $171,000. Seizert Capital Partners LLC purchased a new stake in shares of Kamada in the fourth quarter worth about $194,000. BlackRock Inc. purchased a new stake in shares of Kamada in the second quarter worth about $216,000. Marshall Wace LLP purchased a new stake in shares of Kamada in the first quarter worth about $276,000. Finally, Jane Street Group LLC lifted its holdings in shares of Kamada by 52.8% in the fourth quarter. Jane Street Group LLC now owns 57,872 shares of the biotechnology company’s stock worth $395,000 after buying an additional 19,991 shares in the last quarter. Hedge funds and other institutional investors own 12.97% of the company’s stock.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.
Further Reading: What are the qualifications of a portfolio manager?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.